Skip to content
Q1 '26Q4 '25Q3 '25Q2 '25Q1 '25
Returns
Return on equity-33.6%-3.4pp-30.2%+6.6pp-36.9%-1.1pp-35.7%+19.4pp-55.1%-2.5pp
Return on assets-31.8%-3.7pp-28.1%+6.1pp-34.2%-0.7pp-33.5%+17.5pp-51%-3.2pp
Return on invested capital-45%-2.4pp-42.6%+15.2pp-57.8%+17.6pp-75.3%-2.8pp-72.5%+14.7pp
Liquidity
Current ratio24.8×+5.1×19.7×-2.3×21.9×-0.5×22.4×+7.0×15.4×+5.0×
Quick ratio24.8×+5.1×19.7×-2.3×21.9×-0.5×22.4×+7.0×15.4×+5.0×
Cash ratio2.7×+0.8×1.9×-4.4×6.3×-6.4×12.7×+9.8×2.8×-0.4×
Leverage
Debt-to-equity0.0×0.0×0.0×0.0×0.0×
Debt-to-assets0.0×0.0×0.0×0.0×0.0×
Per Share
Book value per share$1.18-13.1%$1.36+4.0%$1.31-14.1%$1.52+80.1%$0.85-13.5%
Valuation
Market capitalization$1.53B-4.6%$1.61B+44.1%$1.11B+58.6%$702.53M+15.5%$608.13M+65.2%
Enterprise value$1.51B-4.7%$1.59B+50.0%$1.06B+80.5%$586.36M-0.6%$589.71M+76.0%
Price / book8.9×+0.1×8.8×+2.9×5.9×+2.3×3.5×-2.6×6.1×+2.4×
Earnings yield-3%-0.3pp-2.7%+1.5pp-4.1%+2.6pp-6.7%+1.1pp-7.8%+5.2pp

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Questions, answered.

Where do Trevi Therapeutics, Inc.'s ratios come from?
Every ratio is computed from Trevi Therapeutics, Inc.'s SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.